CG Results Healthcare advises Inflexion on its acquisition of Pharmaspectra

We are delighted to announce that CG Results Healthcare has advised Inflexion Private Equity on its acquisition of Pharmaspectra, a leading global provider of medical affairs data to the pharmaceutical and biotech industry. The investment is being made by Inflexion Enterprise Fund IV, Inflexion’s dedicated lower mid-market fund.

Founded in 2005, Pharmaspectra is the leader in providing scientific dissemination data and analytics to the pharmaceutical industry. Pharmaspectra’s data is utilised by seven of the world’s top ten pharmaceutical companies. The firm has offices in the UK, US, Switzerland, and India.

With Inflexion’s backing, Pharmaspectra will be expanding its global footprint in the key markets – US, Europe and Asia and accelerating new product development.

This deal represents our eighth deal advising companies in the pharma services sector in the last 12 months including Linguamatics on its acquisition by a Tier-1 CRO and Arxspan on its acquisition by Bruker. It demonstrates our strong track record within the pharma community of investors and decision makers, built on our long-standing reputation advising companies across the healthcare and life sciences sector.